Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2015

View Archived Issues

Isis Pharmaceuticals updates on phase II trial of ISIS-SMNRx in infants with type I SMA

Tioga Pharmaceuticals begins phase II study of asimadoline in patients with pruritus

NCCN receives funding from Boehringer Ingelheim to study afatinib combinations in NSCLC

Merrimack expands MM-398 imaging study to patients with metastatic breast cancer

Adamas starts phase II trial of amantadine ER in patients with MS and walking impairment

Immune Pharmaceuticals licenses topical ciclosporin formulation from Yissum

Johnson & Johnson announces multiple collaborations

First preclinical data presented on ORM-23048 for neuropathic pain

Bristol-Myers Squibb patents EZH2 inhibitors

Canadian scientists describe withanolide analogues

Pharmakea discloses autotaxin inhibitors

Tolerability and activity assessed with ASP-2215 in patients with acute myeloid leukemia

PTC Therapeutics develops BMI-1 inhibitors

Daiichi Sankyo divulges LCAT activators

Novel DNA vaccine shows promising preclinical efficacy

New antibody for IBD tested at Sumitomo Dainippon Pharma

FDA awards breakthrough therapy designation to SER-109

Novel Nanofitin targeting TNF-alpha for IBD

Cancer vaccine developer Targovax merges with oncolytic virus firm Oncos

First phase I/II data for Delta-Fly Pharma's DFP-10917 in acute myeloid leukemia

KemPharm reports data from abuse liability trial of KP-201/acetaminophen

Servier licenses European rights to Taiho's TAS-102

BioAtla receives equity investment from Chinese investor group

Roswell Park Cancer Institute spins out OmniSeq

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...